Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

Mainz Biomed (MYNZ) EBITDA (2022 - 2023)

Historic EBITDA for Mainz Biomed (MYNZ) over the last 2 years, with Q4 2023 value amounting to -$47.6 million.

  • Mainz Biomed's EBITDA fell 46719.36% to -$47.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$26.8 million, marking a year-over-year decrease of 37735.02%. This contributed to the annual value of $21.8 million for FY2024, which is 18117.55% up from last year.
  • Per Mainz Biomed's latest filing, its EBITDA stood at -$47.6 million for Q4 2023, which was down 46719.36% from $5.8 million recorded in Q3 2023.
  • Mainz Biomed's 5-year EBITDA high stood at $8.3 million for Q2 2023, and its period low was -$47.6 million during Q4 2023.